Stem Cell Transplantation More Cost-Effective than Gene Therapy for Sickle Cell Disease
Stem cell transplantation is the most cost-effective option for long-term care of sickle cell disease in adults when compared with gene therapy and standard of care treatment, according to new…
Pfizer’ s BRAFTOVI* Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer #ASCO26
Pfizer announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (ERBITUX®) and FOLFIRI…
Experts call for women’s heart centres to tackle inequality in diagnosis & care
Women are more likely to face delays in diagnosis of cardiovascular disease and, as a result, they are more likely to die or develop more serious illness. To address this…
59.000 deaths: Europe off track for sustainable development goal targets for HIV, tuberculosis, viral hepatitis, and STIs
Despite advancements in detection and treatment, a new report reveals severe shortfalls in reaching the indicators for the Sustainable Development Goal target for HIV, tuberculosis, viral hepatitis and sexually transmitted…
ECDC: Questions and answers on the hantavirus outbreak in a cruise ship
What is hantavirus and the Andes strain? Hantaviruses are a group of viruses that people usually catch through particles from infected rodents. It can cause serious illness, and the symptoms…
Anti-amyloid Alzheimer’s drugs show no clinically meaningful effect
People with Alzheimer’s disease have high levels of a protein known as amyloid beta in their brains, detectable before symptoms begin, but its role in disease progression is uncertain. Drugs…
500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause
A new treatment option for menopausal hot flushes and night sweats can be used in the NHS when hormone replacement therapy (HRT) is not suitable Fezolinetant (Veoza*) is recommended to…
Thymidine Kinase 2 Deficiency (TK2d): European Commission approves doxecitine and doxribtimine (KYGEVVI®) as first and only treatment
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that the European Commission (EC) has granted marketing authorization under exceptional circumstances for KYGEVVI (doxecitine and doxribtimine) for the treatment…
Cases of invasive meningococcal disease notified in Kent
The UK Health Security Agency is continuing to investigate an outbreak of meningococcal disease in Kent. As of 5pm on 19 March, 18 laboratory cases are confirmed and 11 notifications…
First-ever in-utero stem cell therapy for fetal spina bifida repair is safe. The Lancet
A phase 1 clinical trial published in The Lancet has shown that combining stem cell therapy with standard fetal surgery before birth is a safe and promising approach to treat…